Onset and Maintenance of No Evidence of Disease Activity With Ublituximab: Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multiple Sclerosis

site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
Drug Category : Array
Conference Category : Array
Lead Author : Alvarez E, et al.
Published Date : 23/02/2023
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2023/02/P082_Alvarez.pdf
Download Text : Download
Popup Confirmation? :
astra-migrate-meta-layouts : set
Scroll to Top